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Objectives: To compare propofol and midazolam in adult intensive care patients in
relation to length of ICU stay, length of mechanical ventilation (MV) and time until
extubation. Methods: MEDLINE, EMBASE, LILACS and Cochrane databases were
searched from inception until July 2019 to retrieve RCTs that compared propofol and
midazolam use as sedatives in adult ICU patients. There was no language restriction.
We extracted and combined data from studies that reported to length of ICU stay,
length of MV and time until extubation. A random-effects, meta-analytic model was
applied in all calculations. Cochrane collaboration tool and GRADE were used to
assess bias and certainty of the outcomes of the included studies, respectively. Two
groups of patients were analyzed: elective surgical patients and critically ill patients.
Results: Elective surgical patients receiving propofol reduced ICU stay by 5.07 hours
(MD -5.07; 95% CI -8.68 to -1.45; p ,0.006, I2 = 41 %, 5 studies), MV time by 4.28
hours (MD -4.28; 95% CI -4.62 to -3.94 (p,0.00001, I2 = 0, 3 studies), extubation time
by 1.92 hours (MD -1.92; 95% CI -2.71 to -1.13; p ,0.00001, I2 = 89%, 9 studies)
compared to patients receiving midazolam. Critically ill patients receiving propofol
reduced extubation time by 32.68 hours (MD -32.68; 95% CI -48.37 to -16.98; p
,0.0001, I2 = 97%, 7 studies) compared to patients receiving midazolam. GRADE was
very low for all outcomes. Conclusions: We conclude that propofol is a safe sedation
strategy for general and elective surgery patients in the ICU. It is associated with
improved outcomes when compared to the use of midazolam. Our data is in
accordance with the recent sedation guideline (PADIS) recommendations where
propofol can be used as the first-line sedative in adult ICU patients.
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Objectives: To develop, validate and use streamlined bridging-to-effectiveness
modeling tool for clinical and HTA decision support. Methods: A generic R-based
Bayesian dynamic model was built to allow for virtual patient-level cohort simula-
tions of both exposure and clinical outcomes. This simulation platform relies on
identification and quantification of drivers of disease progression and drug effec-
tiveness. Longitudinal sequences of treatment and outcome patterns are modeled
with competing hazard functions and then mapped into Markov cohort or Discrete
Event Simulation economic models to allow for real-world cost-effectiveness ana-
lyses. This disease-agnostic tool was tested to generate evidence to support long
term effectiveness predictions, performance-based pricing rationales, optimal study
design, positioning or prescription decisions. Results: The tool was successfully
applied in a dozen of access situation across various indications, shortening
modelling time by a .10-fold factor. In an oncology example supporting outcome-
based pricing, the tool showed a 2-fold difference in predicted survival between
trials-based predictions vs. modelled effectiveness. In a cardiovascular example, long
term morbidity and mortality predictions were matching cohort data validation
resulting in higher pricing decisions. In Hodgkin’s lymphoma, extrapolation between
progression-free and overall survival was validated and used for regulatory support.
Conclusions: Such tool allows for fast evidence-based decision support for market
access.
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EFFECTIVENESS OF IMPLEMENTATION OF
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Objectives: Antimicrobial stewardship programmes (ASPs) aims to optimize anti-
biotic use and minimize antimicrobial resistance. From 2017 to 2021, India is
implementing the National Action Plan on Antimicrobial Resistance to combat AMR
and improve antibiotic use. The use of ASPs is increasing in developing countries like
India, but their effectiveness in antibiotic consumption and their impact on clinical
outcomes is not clear. The objective of the study is to assess the efficacy of ASPs and
quality of ASPs conducted in India by using systematic review and meta-analyses.
Methods: Electronic databases Pubmed, Embase and Google scholar were searched
from inception to September 2019 for studies evaluating any ASPs in the community
or hospital setting, without restriction on study design or outcome. Efficacy outcome
like defined daily dose, length of stay, risk of mortality, improvement in rational use
of Antimicrobials were used to assess the effectiveness of ASPs. Random effects
models was used to pool the studies. Results: 11 studies, which evaluated the ASPs
on N= 5484 subjects were included in this systematic review and five studies were
conducted at private setting and remaining studies were at private tertiary care
clinics. Among the included studies, following key strategies were used as ASPs:
Prospective audit with feedback (n =4), formulary restriction (n =3), preauthorization
(n =3), and guidelines (n =1). After implementation of ASPs, clinic outcomes defined
daily dose (mean difference (MD); -11.64 (95% CI: -42.22 to 18.93) and length of stay
(MD; 0.08 (95% CI -2.51 to 2.6) were reduced significantly. The pooled relative risk of
mortality rate was 0.88 (95% CI = 0.77–1.001). Conclusions: The findings of this
systematic review concludes that, Even though implementations of ASPs improved
clinical outcomes, there was huge variation in the implementations ASPs in hospital
and clinic settings in India. Hence we need proper guidelines in implementation of
the ASPs.
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Objectives: The Treatment Satisfaction Questionnaire for Medication (TSQM) is the
most commonly used generic Patient-Reported Outcome (PRO) instrument
measuring treatment satisfaction. Its psychometric properties have been rigorously
assessed in paper form. Only recently has the electronic format of the TSQM been
developed. Current guidance recommends assessing measurement equivalence of
minor changes to the electronic migrations of paper PROs by usability testing and
cognitive debriefing with patients. This study aimed to determine the usability of the
electronic version of the TSQM. Cognitive interviews have been shared elsewhere.
Methods: Electronic versions of both the TSQM v1.4 and vII were tested for usability.
A electronic survey was conducted among subjects of an online patient community
managed by IQVIA (MediGuard) in the US and in the UK. The survey included the
TSQM and questions related to sociodemographics, disease diagnoses and treatment,
and medical device use. Two TSQM items were randomly selected for concurrent
probing, using item-specific usability questions, and retrospective probing, using
general usability questions. This study represents a subset of the data collected.
Results: The survey was completed by 108 and 354 patients in the UK and in the US,
respectively. Most patients who responded had university-level education (67%), and
most were female (68%). Mean (SD) age was 50 (618.4) years. Patients had a wide
variety of medical conditions and completed the survey on a smartphone (n=59%),
computer (23%) or a tablet (18%). Most patients reported that the electronic versions
of the TSQM (v1.4 and vII) were readable or very readable (92%), and they were able
to select the response options appropriately with the device they used (98%) Con-
clusions: The usability of the eTSQM (v1.4 and vII) was obtained through concurrent
and retrospective probing quickly using an online qualitative approach.
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Objectives: To estimate the prevalence and associated factors to psychotic substance
use in low-income adolescents from the Caribbean region of Colombia Methods: A
cross sectional study was conducted. Adolescents between 10-24 years of age resi-
dents in 21 municipalities were randomly selected from the population affiliated to a
subsidized-regime insurance company between 2014-2018. A previously constructed
questionnaire was used to obtain information regarding sociodemographic variables
and potential risk factors. Prevalence of lifetime use of substance abuse was assessed.
Bivariate and multivariate logistic regression models were used to establish associ-
ated factors. Absolute and relative frequencies were compared with the Chi2 test and
continuous variables were compared with the t-test. A p value ,0.050 was consid-
ered significant Results: A total of 35,214 adolescents with a mean (SD) age of 16.0
(4.1) years were included. Of these, 55.7% were women and 63.9% lived in urban
areas. The lifetime prevalence of psychoactive substance use was 1.9% (95% CI: 1.7-
2.0) and a higher prevalence of use was found in males compared to females (2.8%
and 1.1%). A positive association between age and substance use was found (10-14yr:
0.7%; 15-19yr: 2.4% and 20-24yr: 2.9%). Compared to tobacco (4.4%), alcohol (28.8%)
was the most frequent substance consumed by individuals. Risk factors for substance
consumption were (OR 95% CI) being older than 14 years (15-19yr=OR 3.2; 2.4-4.2
and 20-24yr=OR 4.4; 3.3-5.8)(p,0.001), feeling sad/empty most of the time (OR 2.3;
1.8-2.9), having suffered constant physical abuse by parents (OR 2.8; 1.0-6.9), have
executed school bullying (OR 2.0; 1.5-2.6) and urban residence (OR 1.6; 1.3-2.1).
Conclusions: a correlation between substance use and adverse outcomes in mental
health, family function and quality of life was found. Policies should consider the
influence of social determinants of health in the consumption of psychotic sub-
stances in adolescents
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